Award details

Generation, characterisation and application of SARS-CoV-2 protein antigens for COVID-19 rapid diagnostic purposes in the hospital and community

Reference	BB/V011324/1
Principal Investigator / Supervisor	Professor Christopher Smales
Co-Investigators / Co-Supervisors	Professor Anne Dell, Professor Stuart Haslam, Professor Martin Warren
Institution	University of Kent
Department	Sch of Biosciences
Funding type	Research
Value (£)	418,025
Status	Completed
Type	Research Grant
Start date	02/09/2020
End date	01/12/2021
Duration	15 months

Abstract

unavailable

Summary

We aim to generate a range of stably transfected cell lines to help meet the demand for quality-verified recombinant SARS-CoV-2 structural proteins, which are desperately needed, and which we will use, to help in the development of diagnostics and vaccines. In so-doing our project will complement and expand the repertoire of proteins available on the COVID-19 Protein Portal. The platforms we establish will also be perfectly positioned for the rapid generation of other targets in the future. We will produce these in two different mammalian expression systems, CHO and HEK293 cells, characterise these by mass spectrometry and undertake glycosylation analysis of the Spike glycoprotein. In producing non-glycosylated forms of the protein for comparison, we will define the importance of this post-translational modification for folding, assembly of the trimer form and the ability of the protein to detect anti-spike antibodies from recovered COVID-19 patients. The recombinant authentic and characterised forms of the SARS-CoV-2 proteins will be assessed in diagnostic assays in development with our industrial partner Mologic, and in ELISA assays in the East Kent Hospital Trust at Ashford to profile antibody responses across recovered COVID-19 patients. The proposed research will address the WHO 'coordinated global research roadmap 2019 Novel Coronavirus Global Research and Innovation forum' that stipulates the need for reagents that support the development of 'reliable serological testing as well as assays that monitor response and midterm support development of diagnostic products to improve clinical processes to contribute to control/point of care' and for development of vaccines.

Committee	Not funded via Committee
Research Topics	Industrial Biotechnology, Microbiology
Research Priority	X – Research Priority information not available
Research Initiative	Covid19 Rapid Response [2020]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search